European Patent Convention

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Retrieved on: 
Wednesday, December 27, 2023

The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.

Key Points: 
  • The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.
  • In the study, AV-101 prodrug was systematically administered in four rat models of pain to examine its analgesic and behavioral profile.
  • The preclinical study was conducted by Tony L. Yaksh, PhD, Professor of Anesthesiology and Pharmacology at the University of California, San Diego.
  • Vistagen plans to seek potential strategic collaborations to further advance the clinical development and commercialization of AV-101.

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

Retrieved on: 
Tuesday, December 26, 2023

The European Patent office granted patent No.

Key Points: 
  • The European Patent office granted patent No.
  • 3105587 titled 'Method of Qualifying of Cells' for a method of qualifying whether a cell population is a suitable therapeutic for treating ALS.
  • The patent also grants claims for an isolated population of mesenchymal stem cells for use in treating ALS.
  • Securing this European patent, alongside our existing patents in the US, Canada, Israel, Brazil, and Japan, enhances our capability to forge new global commercial partnerships, further expanding the reach of NurOwn."

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

Retrieved on: 
Thursday, November 16, 2023

3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates.

Key Points: 
  • 3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates.
  • The pure SERCA2a Activators are one of two families of preclinical drug candidates that act on SERCA2a in the Company’s pipeline.
  • The new European patent, titled: “ANDROSTANE DERIVATIVES WITH ACTIVITY AS PURE OR PREDOMINANTLY PURE STIMULATORS OF SERCA2A FOR THE TREATMENT OF Heart Failure,” provides patent protection until October 9, 2039 for the family of compounds with the pure SERCA2a mechanism of action.
  • Windtree believes activation of SERCA2a represents a potentially important advancement in heart failure treatment for patients,” said Craig Fraser, CEO of Windtree Therapeutics.

Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine

Retrieved on: 
Friday, November 10, 2023

November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has received an “Intention to Grant” notice from the European Patent Office (EPO) for its patent application titled “Intranasal Composition Comprising Betahistine” (designated as European Patent 3698791).

Key Points: 
  • November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has received an “Intention to Grant” notice from the European Patent Office (EPO) for its patent application titled “Intranasal Composition Comprising Betahistine” (designated as European Patent 3698791).
  • The application is a continuation of the previously granted European Patent 3474850 and upon issuance, is expected to remain valid until February 2038.
  • Combined, these two patents will provide key intellectual property protection for the Company's intranasal betahistine program (AM-125) in Europe.
  • “We are very pleased with the continued expansion of our patent portfolio covering the intranasal betahistine program,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO.

Takara Bio USA Wins EU Opposition Hearing, Revoking Jumpcode Genomics’ NGS Library Enrichment Patent

Retrieved on: 
Monday, December 11, 2023

Takara Bio USA, Inc. today announced that it has once again prevailed in its second patent dispute with Jumpcode Genomics, Inc.

Key Points: 
  • Takara Bio USA, Inc. today announced that it has once again prevailed in its second patent dispute with Jumpcode Genomics, Inc.
  • Following a hearing before the Opposition Division of the European Patent Office on November 28, the European Patent Office revoked Jumpcode’s patent in its entirety, with no claims allowed.
  • This contrasts with Jumpcode’s earlier challenge to Takara Bio USA’s European Patent (EP3105325), which the European Patent Office upheld following a similar hearing last year.
  • This latest decision reinforces the strength of Takara Bio USA’s European patent and portfolio, which supports some of our most innovative RNA-seq technologies,” said Carol Lou, President & CEO of Takara Bio USA.

Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings

Retrieved on: 
Tuesday, November 28, 2023

Vedanta Biosciences , a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational patents EP3178483B1, EP3552613B1, and EP3539548B1 (the “Honda patents”) in oral opposition proceedings held in Munich over the course of three weeks.

Key Points: 
  • Vedanta Biosciences , a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational patents EP3178483B1, EP3552613B1, and EP3539548B1 (the “Honda patents”) in oral opposition proceedings held in Munich over the course of three weeks.
  • In all three cases, the originally granted claims of the patents were upheld without any modification and were deemed valid and supported by the EPO.
  • The Honda patents are based on groundbreaking work at the lab of Dr. Kenya Honda, a scientific co-founder of Vedanta, which identified clostridial bacteria that induce significant immune responses.
  • The Honda patents, together with additional Vedanta patents, provide the company with a leading IP position in the microbiome field.

The European Patent Office (EPO) Rules in Favor of Mara and AO3 on Validity of DSM Patent EP3530740

Retrieved on: 
Monday, November 27, 2023

Mara Renewables Corporation, and its manufacturing partner Algal Omega-3 (AO3) announced today that the European Patent Office (EPO), Opposition Division, has ruled in favor of Mara regarding the validity of DSM’s patent EP3530740, titled “Thraustochytrids, fatty acid compositions, and methods of making and uses thereof.”

Key Points: 
  • Mara Renewables Corporation, and its manufacturing partner Algal Omega-3 (AO3) announced today that the European Patent Office (EPO), Opposition Division, has ruled in favor of Mara regarding the validity of DSM’s patent EP3530740, titled “Thraustochytrids, fatty acid compositions, and methods of making and uses thereof.”
    The EPO panel decided the DSM patent as granted is not valid and that its scope must be significantly narrowed.
  • As a result, the microbial oils claimed by the patent are now limited to those containing at least 60% DHA in the triglyceride fraction, up from a previous limit of at least 50% DHA.
  • “We are pleased with the decision of the EPO opposition division.
  • We will also look to enforce our own intellectual property in a responsible manner.

Cybin Reports Second Quarter Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, November 15, 2023

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September 30, 2023, and recent business highlights.

Key Points: 
  • Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September 30, 2023, and recent business highlights.
  • “We have made enormous progress during the past quarter, with ample momentum to carry us through year-end and into 2024.
  • Announced unprecedented positive Phase 2 interim data for CYB003, the Company’s proprietary deuterated psilocybin analog, in major depressive disorder (“MDD”).
  • Cash-based operating expenses totaled C$12.5 million for the quarter ended September 30, 2023, compared to C$11.3 million, in the prior year quarter, of which C$2.1 and C$2.0 million were one-time costs, respectively.

Darling Ingredients' health brand Rousselot receives U.S. Patent for gelatin technology that improves soft gel capsule stability and efficacy

Retrieved on: 
Monday, December 4, 2023

11795489B2 to its health brand Rousselot, securing Rousselot's intellectual property rights for StabiCaps™, a specialized gelatin that improves the formulation and stability of soft gel capsules to enhance the release of active ingredients, including medications.

Key Points: 
  • 11795489B2 to its health brand Rousselot, securing Rousselot's intellectual property rights for StabiCaps™, a specialized gelatin that improves the formulation and stability of soft gel capsules to enhance the release of active ingredients, including medications.
  • StabiCaps addresses crosslinking, a common challenge in the dissolution of soft gel capsules that results in slower or incomplete release of nutrients or pharmaceutical ingredients contained within the capsule.
  • "StabiCaps is an essential innovation for soft gel capsule manufacturers because gelatin is a primary ingredient," said Pierre-Albert Thomas, Rousselot Functional Ingredients Director.
  • "With this new patent, soft gel manufacturers in the U.S. can unlock the benefits of StabiCaps gelatin technology to produce high quality soft gel capsules with longer shelf stability and improved efficacy for customers."

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Retrieved on: 
Monday, November 27, 2023

SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines."

Key Points: 
  • SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines."
  • Dr. Amit Kumar, Chairman and CEO of Anixa, stated, "Having recently been granted a U.S. patent for this novel ovarian cancer vaccine technology, we are delighted to receive the EPO's intention-to-grant notice, as a European patent would extend protection of the technology to additional potential markets."
  • The patent was invented by the late Dr. Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic.
  • Anixa exclusively licensed the technology from Cleveland Clinic and is developing the technology in partnership with the not-for-profit, multispecialty academic medical center.